Series A
$300M
Bain Capital · Lead
Open roles0
Total raised$300M
Team size11-50
Founded · Stage2025 · Series A
We pull jobs from sources most job seekers never check
About the company
What they build and who they serve.
Boston-based clinical-stage biotech developing precision therapies for autoimmune and inflammatory diseases. Emerged from stealth with five programs licensed from Bristol Myers Squibb, including Phase 2 lupus candidate afimetoran and novel IL-2 assets. Led by CEO Saqib Islam, who previously guided Pfizer's immunology portfolio. Focuses on precision immunology — targeting the right patients with the right therapy at the right time.
Why it matters
Signals from funding, traction, and product direction.
- Emerged from stealth with five autoimmune programs licensed from Bristol Myers Squibb, including Phase 2 lupus candidate afimetoran
- Led by CEO Saqib Islam (former Pfizer immunology portfolio leader); $300M is among the largest biotech Series A rounds of 2026
- Focuses on precision immunology — novel IL-2 and other immune-modulating therapies for autoimmune and inflammatory diseases
Funding history
Rounds and investors over time, newest first.
In the news
Press, announcements, and coverage about this company.
Investors
Bain Capital
Focus areas
Series ABiotechnologyClinical TrialsHealthtech
No open roles on the board yet
We do not have indexed listings for Beeline Medicines right now. Roles may still be open on the company site—we will add them here when they appear in our feed.
Don’t get beat to tomorrow’s openings
New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job posts